Table 1 Baseline characteristics of the study populations (n = 232)

Demographic data

Age, years

33.1 ± 8.7

33.2 ± 7.3

28.5 ± 9.5 ^b

26.6 ± 7.4,

24.6 ± 6.6

Female, n (%)

28 (47.5)

83 (66.4)

6 (46.2)

6 (60)

16 (64)

Clinical data

CHBV coinfection, n (%)

11/57 (19.3)

8/112 (7.2)

3 (15)

2 (20)

1 (4)

WHO stage, n (%)

  I + II

3/50 (6)

80 (64)

  III + IV

47/50 (94)

45 (36)

NA

NA

NA

BMI, kg/m2

18.9 ± 3.1^a

21.3 ± 3.5

18.9 ± 2.8

21.4 ± 2.5

21.4 ± 2.0

BMI < 18.50 kg/m², n (%)

29 (49.2)

18/124 (14.6)

6 (46)

8 (80)

24 (96)

Laboratory data

Hgb, g/dl

12.2 ± 3.7 ^a

13.2 ± 2.5

13.5 ± 2.5 ^b

16.4 ±1.8 ^c

18.0 ± 2.1

Hgb < 12 g/dl (anemic), n (%)

23/43 (53.5)

29/107 (27.1)

2 (23)

0

0

CD4+ count/μl

173.7 ± 180.8 ^a

279.2 ± 212.4

478.1 ± 253 ^b

787.3 ± 274

754.8 ± 241

CD4+ category, n (%)

  < 100

27 (48.2)

26 (22.2)

1 (1.7)

0

0

  100 –200

12 (21.4)

26 (22.2)

6 (10.0)

0

0

  > = 201

17 (30.3)

65 (55.6)

53 (88.3)

10 (100)

25 (100)

TLC

1175 ± 754 ^a

1626 ± 750

1485 ± 895 ^b

1975 ± 1483

1.668 ± 559

HIV RNA (log10copies/ml)

4.5 ± 0.8 ^a

4.1 ± 0.9

NA

NA

NA

HIV RNA category, n (%)

  LDL

1 (2.2)

9 (8.0)

  <= 100000

14 (30.4)

97 (85.8)

  >100000

32 (69.6)

16 (14.2)

NA

NA

NA